Phase 4Terminated
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
- Sponsor
- Theratechnologies (Industry)
- Enrollment
- 129 enrolled
- Conditions
- Diabetic Retinopathy; HIV
- Interventions
- Tesamorelin; Placebo-Control
- Ages
- adults, older adults
- Registry
- NCT01591902
Full record on ClinicalTrials.gov
From the registry
To show the non-inferiority of EGRIFTA® vs. placebo in the development or progression of Diabetic Retinopathy in HIV-infected subjects with concomitant abdominal lipohypertrophy and Type 2 diabetes mellitus (T2DM).
Primary outcomes
- Difference in percentages of subjects with a 3-step or greater progression (from both eyes) on the Early Treatment Diabetic Retinopathy Study (ETDRS) PERSON scale.
History
Last registry update
Study completion
Primary completion
Started
Registered